Analysis of Effectiveness, Safety, and Bleeding Related to Rivaroxaban in Elderly Patients

9Citations
Citations of this article
24Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

This study explored the efficacy and safety of rivaroxaban in elderly patients, at different doses and age of patients, and analyzed risk factors of bleeding. A retrospective analysis was conducted of 299 patients aged 60 years or older who were admitted to the First Hospital of Jilin University between January 2016 and August 2018. It was found that the rate of bleeding events (but not embolism) significantly increased as the dose of oral rivaroxaban increased (P

Cite

CITATION STYLE

APA

Hou, H., Li, A., Zhang, L., Qin, X., Jiang, Y., & Zhao, H. (2020). Analysis of Effectiveness, Safety, and Bleeding Related to Rivaroxaban in Elderly Patients. Clinical and Applied Thrombosis/Hemostasis, 26. https://doi.org/10.1177/1076029620925923

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free